If this box remains here for more than 30 seconds, click this link to try again.
Products & Services »
Best Practice Database
Medical Affairs » Patient Advocacy
Download FREE Excerpt
11 Info Graphics
13 Data Graphics
Single User: Authorizes use by the person who places the order or for whom the order was placed.
Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.
Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.
Patient advocacy groups play a crucial role in educating consumers on new medicines and treatments. Collaboration between biopharmaceutical organizations and advocacy groups offers the opportunity for a win-win partnership. These partnerships are predicated on starting and maintaining positive relationships with patient advocacy groups.
This study explores the tools and tactics that have proven effective in creating and managing relationships with patient advocacy groups. Further, this study reviews the use of new technologies to reach patient advocacy groups as well as patients, and the role of advocacy group collaborations during the product lifecycle. Companies can use the key benchmark metrics, executive insights, recommendations, best practices, lessons learned and pitfalls to avoid to more effectively create and maintain relationships with patient advocacy groups.
Centralized pharmaceutical advocacy leadership and regular priority setting are the most effective approaches for setting shared objectives with advocacy groups. A variety of approaches are useful for prioritizing which patient advocacy group relationships to pursue. “Periodic priority setting” and “centralized leadership” rank most highly effective, followed by “committee arbitration” and “clear roles and responsibilities.”
Insights are drawn from survey responses from a total of 58 research participants at 43 pharmaceutical, biotechnology, and medical device companies. More than a dozen in-depth interviews were conducted to gather more detailed information pertinent to this study. Approximately half of the benchmark class (28 participants) consisted of executives representing top 50 bio-pharmaceutical companies.